Citation

Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, di Giannantonio M. Hum. Psychopharmacol. 2015; 30(4): 265-271.

Affiliation

Department of Neuroscience and Imaging, University 'G. d'Annunzio', Chieti, Italy.

Copyright

(Copyright © 2015, John Wiley and Sons)

DOI

10.1002/hup.2410

PMID

26216561

Abstract

OBJECTIVE: The urge to gain information on a new drug marketed online as 'Psyclone' has emerged after the death of a 38-year-old man in Bolton (UK). The fatality appeared to be a consequence of smoking this psychoactive product.

METHODS: From October to December 2013, qualitative searches of the Web have been carried out in English and Italian, using the keywords 'Psyclone', 'Psyclone legal high', 'Psyclone incense' and 'Psyclone research chemical' on the Google search engine and on the database provided by the Global Public Health Intelligence Network.

RESULTS: Our research highlighted the existence of two psychoactive products labelled as Psyclone but with different contents and packaging: a herbal blend containing two synthetic cannabinoids (AKB-48 and 5f-PB-22) and a research chemical containing 50% ethylphenidate, 30% caffeine and 20% lidocaine. Desired and side effects of both compounds are explored in the paper.

CONCLUSIONS: Being sold as a legal product, Psyclone may appeal to recreational users, who remain unaware of its real content. This is a serious public health threat, which may lead to acute intoxications and fatalities. Further studies in the field, including Internet monitoring, are therefore required.

Language: en